(Q43545518)

24 November 2017

title

Comparative study of HMG-CoA reductase inhibitors on fibrinogen (English)

1 reference

24 November 2017

Rosenson RS

1

1 reference

24 November 2017

Tangney CC

series ordinal

2

1 reference

24 November 2017

Schaefer EJ

series ordinal

3

1 reference

24 November 2017

publication date

1 April 2001

1 reference

24 November 2017

1 reference

24 November 2017

volume

155

1 reference

24 November 2017

issue

2

1 reference

24 November 2017

page(s)

463-466

1 reference

Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies

24 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900590-6

Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900590-6

Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM study in healthy men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900590-6

Antiatherothrombotic properties of statins: implications for cardiovascular event reduction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900590-6

Effects of lipids and lipoproteins on thrombosis and rheology.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900590-6

[Rapid physiological coagulation method in determination of fibrinogen]

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900590-6

Intraindividual variability of fibrinogen levels and cardiovascular risk profile.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900590-6

Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900590-6

Fibrinogen, viscosity and the 10-year incidence of ischaemic heart disease: The Caerphilly and Speedwell Studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900590-6

Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900590-6

Atorvastatin: an effective lipid-modifying agent in familial hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900590-6

Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900590-6

10.1016/S0021-9150(00)00590-6

7 January 2021

Identifiers

DOI

1 reference

24 November 2017

1 reference